Profile data is unavailable for this security.
About the company
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
- Revenue in USD (TTM)78.50m
- Net income in USD-367.30m
- Incorporated2014
- Employees445.00
- LocationArvinas Inc5 Science ParkNEW HAVEN 06511-1966United StatesUSA
- Phone+1 (203) 535-1456
- Fax+1 (302) 636-5454
- Websitehttps://www.arvinas.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sana Biotechnology Inc | 0.00 | -283.26m | 1.97bn | 328.00 | -- | 6.19 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.02bn | 1.76k | 15.94 | 3.10 | 11.35 | 3.13 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
Keros Therapeutics Inc | 151.00k | -152.99m | 2.03bn | 136.00 | -- | 5.40 | -- | 13,469.29 | -5.19 | -5.19 | 0.0051 | 10.43 | 0.0005 | -- | 2.11 | 1,110.29 | -45.21 | -35.95 | -48.12 | -38.07 | -- | -- | -101,319.20 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Intellia Therapeutics Inc | 36.28m | -481.19m | 2.06bn | 526.00 | -- | 1.90 | -- | 56.70 | -5.42 | -5.42 | 0.4106 | 11.29 | 0.0257 | -- | 1.80 | 68,963.88 | -34.11 | -31.34 | -37.31 | -34.53 | -- | -- | -1,326.51 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
Maravai Lifesciences Holdings Inc | 288.95m | -119.03m | 2.06bn | 650.00 | -- | 4.94 | -- | 7.13 | -0.901 | -0.901 | 2.19 | 1.66 | 0.1533 | 3.15 | 2.99 | 444,530.80 | -7.34 | 12.67 | -9.75 | 15.46 | 48.52 | 74.79 | -47.89 | 37.32 | 7.41 | -0.3566 | 0.4134 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Kymera Therapeutics Inc | 78.59m | -146.96m | 2.06bn | 187.00 | -- | 4.73 | -- | 26.25 | -2.52 | -2.52 | 1.35 | 7.11 | 0.1333 | -- | 7.38 | 420,278.10 | -24.93 | -23.03 | -28.76 | -27.64 | -- | -- | -186.99 | -207.82 | -- | -- | 0.0065 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 2.08bn | 355.00 | -- | 5.80 | -- | 12.72 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
TG Therapeutics Inc | 233.66m | 12.67m | 2.11bn | 264.00 | 967.42 | 12.89 | 163.73 | 9.03 | 0.0141 | 0.0141 | 1.61 | 1.06 | 0.8933 | -- | 9.15 | 885,087.10 | 4.84 | -62.87 | 6.09 | -80.06 | 93.95 | -- | 5.42 | -405.03 | 5.18 | 1.64 | 0.3842 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Vera Therapeutics Inc | 0.00 | -95.99m | 2.15bn | 51.00 | -- | 17.27 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
Arvinas Inc | 78.50m | -367.30m | 2.17bn | 445.00 | -- | 3.27 | -- | 27.65 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Dyne Therapeutics Inc | 0.00 | -235.94m | 2.18bn | 141.00 | -- | 17.04 | -- | -- | -3.94 | -3.94 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -100.10 | -52.81 | -120.31 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
Guardant Health Inc | 563.95m | -479.45m | 2.19bn | 1.78k | -- | 13.80 | -- | 3.88 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
Denali Therapeutics Inc | 330.53m | -145.22m | 2.20bn | 445.00 | -- | 2.07 | -- | 6.66 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
Vericel Corp | 197.52m | -3.18m | 2.22bn | 314.00 | -- | 9.71 | 1,416.22 | 11.24 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Avidity Biosciences Inc | 9.56m | -212.22m | 2.29bn | 253.00 | -- | 3.82 | -- | 239.64 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Geron Corp | 237.00k | -184.13m | 2.31bn | 141.00 | -- | 8.64 | -- | 9,732.34 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Dec 2023 | 6.73m | 9.88% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 4.71m | 6.92% |
RTW Investments LPas of 31 Dec 2023 | 4.21m | 6.19% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 4.17m | 6.12% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.73m | 5.48% |
Avidity Partners Management LPas of 31 Dec 2023 | 2.99m | 4.38% |
Bellevue Asset Management AGas of 31 Dec 2023 | 2.51m | 3.68% |
Citadel Advisors LLCas of 31 Dec 2023 | 2.36m | 3.47% |
ArrowMark Colorado Holdings LLCas of 31 Dec 2023 | 1.57m | 2.31% |
FIAM LLCas of 31 Dec 2023 | 1.19m | 1.75% |